Chronic hepatitis B virus (HBV) infection is a major global health problem. Current antiviral therapy including pegylated interferon and nucleos(t)ide analogue is effective in reducing progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma but the rate of HBsAg seroclearance is ...
Hepatitis B is a type of virus that causes serious infection in the liver. If not treated on time, hepatitis B can become chronic leading to permanent scarring or failure of liver function. Most often, hepatitis B can lead to major liver dysfunctions suc
The possibility of a great cure hepatitis B 翻译结果2复制译文编辑译文朗读译文返回顶部 Possibility of a cure for hepatitis b great 翻译结果3复制译文编辑译文朗读译文返回顶部 Possibility of a cure for hepatitis b great 翻译结果4复制译文编辑译文朗读译文返回顶部 ...
Chronic hepatitis B (CHB), caused by hepatitis B virus (HBV), is a major cause of advanced liver disease and hepatocellular carcinoma (HCC) worldwide. HBV
Treatment of chronic hepatitis B virus (HBV) infection with the viral DNA polymerase inhibitors or pegylated alpha-interferon has led to a significant retardation in HBV-related disease progression and reduction in mortality related to chronic hepatitis B associated liver decompensation and hepatocellular ...
Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B. Since Contagion's first interview last year with Carter Keller, senior VP at Grifols and head of GigaGen, there has been significant progress in...
of cccDNA in the HBV infectious cycle, this review aims to summarise current knowledge on cccDNA molecular biology, to highlight the experimental restrictions that have hitherto hampered faster progress and to discuss cccDNA as target for new, potentially curative therapies of chronic hepatitis B. Pu...
Case in point: The recent discovery of a biomarker that can predict if an individual will achieve a functional cure of hepatitis B virus (HBV) gave rise to a surge of interest from the pharmaceutical industry in researching curative therapies for HBV. ...
Results from the REP 301 and REP 401 studies showed combination therapy with REP2139 and pegylated interferon led to high rates of hepatitis B seroconversion in patients coinfected with hepatitis B and hepatitis D with more than half of treated patients also achieving functional cure of hepatitis ...
A“sandwich” strategy for functional cure of chronic hepatitis BChronic hepatitis B (CHB) remains a global health problem. Therapeutic vaccination has been successfully employed to treat a subpopulation of CHB patients. Personalized treatment can not only improve therapeutic efficacy, but also decrease...